Cas:94994-15-7 methyl 4-(hydroxymethyl)bicyclo[2.2.2]octane-1-carboxylate manufacturer & supplier

Chemical Name:methyl 4-(hydroxymethyl)bicyclo[2.2.2]octane-1-carboxylate

CAS.NO:94994-15-7

Synonyms:4-carbomethoxybicyclo<2.2.2>octane-1-methanol

Molecular Formula:C₁₁H₁₈O₃

Molecular Weight:198.25900

HS Code:2918199090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:274.1ºC at 760 mmHg

Density:1.175g/cm3

Index of Refraction:1.527

PSA:46.53000

Exact Mass:198.12600

LogP:1.49230

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-carbomethoxybicyclo&lt chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,octane-1-methanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2.2.2&gt Use and application,2.2.2&gt technical grade,usp/ep/jp grade.

Related News: Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely. methyl 4-(hydroxymethyl)bicyclo[2.2.2]octane-1-carboxylate manufacturer The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. methyl 4-(hydroxymethyl)bicyclo[2.2.2]octane-1-carboxylate supplier Under the plan, nonessential hospital staff members who belong to the union would not go to work on Monday. methyl 4-(hydroxymethyl)bicyclo[2.2.2]octane-1-carboxylate vendor Singapore, Australia, New Zealand, and the United States have banned all foreign nationals traveling from China from entering the country. methyl 4-(hydroxymethyl)bicyclo[2.2.2]octane-1-carboxylate factory Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.